2LB.F - Iovance Biotherapeutics, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Show:
Balance Sheet
Cash Flow
Annual
Subscribe to Yahoo Finance Plus Essential to download historical data

Income Statement

Currency in USD. All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.Learn more
Breakdown
ttm
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
0
0
0
0
0
Operating Expense
391,307
398,878
342,703
261,937
206,872
Operating Income
-391,307
-398,878
-342,703
-261,937
-206,872
Net Non Operating Interest Income Expense
1,403
2,985
451
2,356
9,316
Pretax Income
-389,904
-395,893
-342,252
-259,581
-197,556
Net Income Common Stockholders
-389,904
-395,893
-342,252
-259,581
-197,556
Diluted NI Available to Com Stockholders
-389,904
-395,893
-342,252
-259,581
-197,556
Basic EPS
-
-2.49
-2.23
-1.88
-1.59
Diluted EPS
-
-2.49
-2.23
-1.88
-1.59
Basic Average Shares
-
159,259
153,406
138,301
124,336
Diluted Average Shares
-
159,259
153,406
138,301
124,336
Total Operating Income as Reported
-391,307
-398,878
-342,703
-261,937
-206,872
Total Expenses
391,307
398,878
342,703
261,937
206,872
Net Income from Continuing & Discontinued Operation
-389,904
-395,893
-342,252
-259,581
-197,556
Normalized Income
-389,904
-395,893
-342,252
-259,581
-197,556
Interest Income
1,403
2,985
451
-
-
Net Interest Income
1,403
2,985
451
2,356
9,316
EBIT
-391,307
-398,878
-342,703
-261,937
-206,872
EBITDA
-371,415
-
-
-
-
Reconciled Depreciation
19,892
-
13,980
1,140
1,169
Net Income from Continuing Operation Net Minority Interest
-389,904
-395,893
-342,252
-259,581
-197,556
Normalized EBITDA
-371,415
-398,878
-342,703
-260,797
-206,872
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0

Yahoo Finance Plus Essential access required.

Learn more